Eko Health Granted Category III CPT Code for AI Heart Disease Detection Platform

The American Medical Association has issued a Category III Current Procedural Terminology (CPT) code for Eko Health’s SENSORA platform.

Effective July 1, the newly issued Category III CPT code is the first step to coverage and reimbursement for SENSORA, bringing advanced heart disease detection to U.S. clinicians. SENSORA is an advanced early disease detection platform containing U.S. Food and Drug Administration (FDA)-cleared AI algorithms that identify signs of structural heart murmurs, low ejection fraction (Low EF), and arrhythmias, including AFib, in the front-line care setting. It seamlessly integrates with Eko’s CORE 500 digital stethoscope, which embeds advanced ECG technology in a familiar tool.

Heart disease is the leading cause of death in the United States, accounting for about one in every five deaths, according to the CDC. Early detection plays a critical role in improving patient outcomes. By empowering primary care providers to identify cardiac issues earlier, SENSORA enhances proactive care and reduces the burden of advanced heart disease management.

“The AMA’s creation of Category III CPT code for Eko’s AI disease detection algorithms is a major step in increasing access to early heart disease detection,” Eko Health CEO Connor Landgraf said. “This milestone will help enable clinicians to use powerful, validated tools to identify heart disease early, ultimately improving patient outcomes, especially in communities with limited access to specialist care.”

SENSORA’s AI algorithms, validated in clinical and real-world studies, help clinicians detect cardiac disease signs often missed by standard care. An independent clinical validation published in Circulation showed that Eko’s structural heart murmur detection AI doubled sensitivity for structural heart disease compared to an analog stethoscope. Additionally, a Lancet Digital Health study involving more than 1,000 patients confirmed Eko’s low ejection fraction AI accurately detects reduced ejection fraction in primary care, leading to its deployment in over 100 U.K. clinics by the NHS and Imperial College London.

The Category III CPT code reflects SENSORA’s growing role as an essential tool in cardiac care and is expected to expand its use across multiple clinical environments.

Eko Health is a digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, used by more than 500,000 healthcare professionals worldwide, allows them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, Calif., with more than $165 million in funding from ARTIS Ventures, DigiTx Partners, Double Point Ventures, EDBI, Highland Capital Partners, LG Technology Ventures, Mayo Clinic, Morningside Technology Ventures Limited, NTTVC, Questa Capital, and others.